|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Epizyme
400 Technology Square
4th Floor
Cambridge
Massachusetts
02139
U.S.A.
Phone:
617-500-7240
Fax:
617-349-0707
|
Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for the treatment of patients with genetically defined cancers, based on breakthroughs in the field of epigenetics. Genetic alterations in HMTs, a family of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.
Epizyme's personalized therapeutics are exemplified by our two most advanced therapeutic product programs, targeting the HMTs DOT1L and EZH2.
Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia and Lymphoma Society (LLS).
Epizyme was founded in 2007 by Nobel Laureate Professor Robert Horvitz, the David H. Koch Professor of Biology at the Massachusetts Institute of Technology and Professor Yi Zhang of The University of North Carolina Chapel Hill. Using our proprietary product platform, we are creating a product pipeline of novel, potent, and selective small molecule inhibitors (HMTi's) directed to specific enzymes within the 96-member HMT target class. Our experienced management team has collectively been responsible for more than 60 INDs and 7 marketed products and also brings extensive business experience. We have raised $54M to date from leading venture capital firms including Kleiner Perkins Caulfield and Byers, MPM Capital, Bay City Capital, NEA, Astellas Venture Management, and Amgen Ventures. Our partners include Celgene, GSK, Eisai, the Multiple Myeloma Research Foundation, and the Leukemia and Lymphoma Society, and we have realized more than $135M in funding from these partners to date.
Email:
Contact@Epizyme.com
Ownership:
Private
Web Site:
Epizyme
Employees:
Symbol:
|
|
|
Company News |
Epizyme Files Registration Statement for Proposed Initial Public Offering
4/26/2013 11:49:11 AM
More...
|
Epizyme Files for IPO of Up to $69 Million
4/19/2013 7:57:51 AM
More...
|
Epizyme to Partner to Develop DOT1L Companion Diagnostic
4/18/2013 10:03:25 AM
More...
|
Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
3/22/2013 9:36:23 AM
More...
|
Epizyme to Present at Upcoming Conferences in February
2/4/2013 7:09:30 AM
More...
|
Epizyme, Eisai Inc. (ESALF.PK) and Roche (RHHBY) to Develop EZH2 Companion Diagnostic
1/7/2013 10:43:41 AM
More...
|
Epizyme to Present at 31st Annual J.P. Morgan Healthcare Conference 2013
1/3/2013 8:01:10 AM
More...
|
Epizyme In Vivo Data Shows Promise in Personalized Therapeutics Programs for Acute Leukemia and Lymphoma
11/29/2012 9:59:48 AM
More...
|
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
11/20/2012 9:16:49 AM
More...
|
Epizyme to Present at Upcoming Scientific and Financial Conferences in November
10/30/2012 9:05:56 AM
More...
|
|
|
|
 |
|
|
|
|
|
|
|
|
|